Cargando…

Epigenetic state determines inflammatory sensing in neuroblastoma

Immunotherapy has revolutionized cancer treatment, but many cancers are not impacted by currently available immunotherapeutic strategies. Here, we investigated inflammatory signaling pathways in neuroblastoma, a classically “cold” pediatric cancer. By testing the functional response of a panel of 20...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wolpaw, Adam J., Grossmann, Liron D., Dessau, Jessica L., Dong, May M., Aaron, Bailey J., Brafford, Patricia A., Volgina, Darya, Pascual-Pasto, Guillem, Rodriguez-Garcia, Alba, Uzun, Yasin, Arsenian-Henriksson, Marie, Powell, Daniel J., Bosse, Kristopher R., Kossenkov, Andrew, Tan, Kai, Hogarty, Michael D., Maris, John M., Dang, Chi V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2022
Materias:	Biological Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832972/ https://www.ncbi.nlm.nih.gov/pubmed/35121657 http://dx.doi.org/10.1073/pnas.2102358119

Ejemplares similares

Refining immunotherapeutic approaches to high‐risk neuroblastoma based on tumor genomic profiles
por: Grossmann, Liron D., et al.
Publicado: (2020)

GPC2 antibody–drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies
por: Pascual-Pasto, Guillem, et al.
Publicado: (2022)

MYCN-enhanced Oxidative and Glycolytic Metabolism Reveals Vulnerabilities for Targeting Neuroblastoma
por: Oliynyk, Ganna, et al.
Publicado: (2019)

CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
por: Sussman, Robyn T., et al.
Publicado: (2020)

Mutations in PIK3CA are infrequent in neuroblastoma
por: Dam, Vincent, et al.
Publicado: (2006)

MYCN-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling
por: Dzieran, Johanna, et al.
Publicado: (2018)

BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma
por: Randall, Michael P., et al.
Publicado: (2023)

Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma
por: Yagyu, Shigeki, et al.
Publicado: (2016)

Neuroblastoma patient-derived xenograft cells cultured in stem-cell promoting medium retain tumorigenic and metastatic capacities but differentiate in serum
por: Persson, Camilla U., et al.
Publicado: (2017)

Expression and activation of nuclear hormone receptors result in neuronal differentiation and favorable prognosis in neuroblastoma
por: Sainero-Alcolado, Lourdes, et al.
Publicado: (2022)

Integrative discovery of treatments for high-risk neuroblastoma
por: Almstedt, Elin, et al.
Publicado: (2020)

Target Genes of c-MYC and MYCN with Prognostic Power in Neuroblastoma Exhibit Different Expressions during Sympathoadrenal Development
por: Yuan, Ye, et al.
Publicado: (2023)

Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells
por: McNerney, Kevin O., et al.
Publicado: (2020)

Neuroblast differentiation during development and in neuroblastoma requires KIF1Bβ-mediated transport of TRKA
por: Fell, Stuart M., et al.
Publicado: (2017)

Inhibition of fatty acid synthesis induces differentiation and reduces tumor burden in childhood neuroblastoma
por: Ruiz-Pérez, María Victoria, et al.
Publicado: (2021)

LIN28B promotes neuroblastoma metastasis and regulates PDZ binding kinase
por: Chen, Dongdong, et al.
Publicado: (2020)

The Multiple Faces of MNT and Its Role as a MYC Modulator
por: Liaño-Pons, Judit, et al.
Publicado: (2021)

Antibody–Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization
por: Buongervino, Samantha, et al.
Publicado: (2021)

Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma
por: Borankova, Karolina, et al.
Publicado: (2023)

Germline pathogenic variants in 786 neuroblastoma patients
por: Kim, Jung, et al.
Publicado: (2023)

Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma
por: Gamble, Laura D., et al.
Publicado: (2012)

Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma
por: Laetsch, T W, et al.
Publicado: (2014)

Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism
por: Mandriota, Stefano J., et al.
Publicado: (2015)

MIF/CXCR4 signaling axis contributes to survival, invasion, and drug resistance of metastatic neuroblastoma cells in the bone marrow microenvironment
por: Garcia-Gerique, Laura, et al.
Publicado: (2022)

Fibroblasts in the Tumor Microenvironment: Shield or Spear?
por: Alkasalias, Twana, et al.
Publicado: (2018)

The MYCN Protein in Health and Disease
por: Ruiz-Pérez, María Victoria, et al.
Publicado: (2017)

Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study
por: Wang, L L, et al.
Publicado: (2015)

Identification of Cytotoxic Drugs That Selectively Target Tumor Cells with MYC Overexpression
por: Frenzel, Anna, et al.
Publicado: (2011)

A comprehensive characterization of rare mitochondrial DNA variants in neuroblastoma
por: Calabrese, Francesco Maria, et al.
Publicado: (2016)

Common variations in BARD1 influence susceptibility to high-risk neuroblastoma
por: Capasso, Mario, et al.
Publicado: (2009)

BH3 Response Profiles From Neuroblastoma Mitochondria Predict Activity of Small Molecule Bcl-2 Family Antagonists
por: Goldsmith, Kelly C., et al.
Publicado: (2009)

Immune-Based Approaches for the Treatment of Pediatric Malignancies
por: Bosse, Kristopher R., et al.
Publicado: (2020)

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma
por: Zhang, Hai-Feng, et al.
Publicado: (2023)

Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group
por: DuBois, Steven G., et al.
Publicado: (2012)

Targeting mitochondrial metabolism for precision medicine in cancer
por: Sainero-Alcolado, Lourdes, et al.
Publicado: (2022)

Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations
por: Brady, Samuel W., et al.
Publicado: (2020)

TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy
por: McNerney, KO, et al.
Publicado: (2022)

Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial
por: de Alarcon, Pedro A., et al.
Publicado: (2017)

International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee
por: Ambros, P F, et al.
Publicado: (2009)

An Analysis of Medical Care Services for Children With Rare Diseases in the Russian Federation
por: Volgina, Svetlana Ya., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_02bjg3es9g2bjg83pdfngpokq6